Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.49 |
| ▸ | CCR1 | P32246 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.47 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.47 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3748349 | 0.88 | KCNH2 (0.63) | KCNH2KMT2AJAK1HTR2BROCK2 | |
| SCHEMBL4491399 | 0.85 | OPRM1 (0.49) | SIGMAR1MEN1KMT2AOPRM1HTR2B | |
| SCHEMBL7416758 | 0.78 | KCNH2 (0.65) | KCNH2JAK1KCNN3 | |
| SCHEMBL6325942 | 0.77 | SIGMAR1 (0.46) | SIGMAR1MEN1KMT2AOPRM1HTR2B | |
| SCHEMBL11266594 | 0.77 | KCNH2 (0.80) | KCNH2SIGMAR1JAK1GAAMAPT | |
| SCHEMBL9698375 | 0.76 | KCNH2 (0.66) | KCNH2MEN1KMT2AJAK1KCNN3 | |
| SCHEMBL9697190 | 0.76 | KCNH2 (0.66) | KCNH2JAK1KCNN3 | |
| SCHEMBL5006579 | 0.76 | SSTR5 (0.55) | KCNH2HTR2BSSTR5HRH1 | |
| SCHEMBL1101038 | 0.75 | KCNH2 (0.77) | KCNH2SSTR5 | |
| SCHEMBL28406604 | 0.74 | HDAC6 (0.57) | KCNH2TDP1KCNN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212299-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2009-04-08 | — | — | EP | disclosed |
| EP-1212299-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2009-04-08 | — | — | EP | disclosed |
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | MERRILL LYNCH CAPITAL, A DIVISION OF MERRILL LYNCH BUSINESS FINANCIAL SERVICES, INC. AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| US-6903085-B1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | ASTRAZENECA, AB (CH) | 2005-06-07 | — | — | US | disclosed |
| EP-1212299-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca UK Limited (GB) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001014333-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LIMITED (GB) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | CXCR4, CXCR1, CXCR3 | KCNH2 1915/4885SIGMAR1 126/4885MEN1 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.